If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.51
Bid: 3.02
Ask: 4.00
Change: 0.00 (0.00%)
Spread: 0.98 (32.45%)
Open: 3.51
High: 0.00
Low: 0.00
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TMT Patent Update

20 Mar 2008 12:22

PROTEOME SCIENCES plc PRESS RELEASE TMT‚® Patent Update

20th March, 2008. The Board of Proteome Sciences is pleased to confirm to shareholders that it holds issued, granted and enforceable patents for its TMT‚® technology in the major global jurisdictions, including the US and Europe.

Before grant in Europe, the European TMT‚® patent went through an extensive examination process and was exposed to anonymous `third party observations' at that time. These were dismissed and the patent went through to full grant and issued on 13th June 2007 (EP 1275004).

The Board has noted that an opposition has been lodged at the European Patent Office based largely on the same grounds that were made prior to grant through `third party observations'. We will be submitting a full, robust and thorough, response to the opposition in the same way as during the `third party observations'.

Proteome Sciences plc and its patent counsel are in the process of reviewing the opposition. Their initial view is that the opposition does not raise any grounds of objection that prejudice the validity of the patent. These actions confirm the importance and value of the TMT‚® isobaric tandem mass tags.

This does not in any way affect the existing status of the TMT‚® patent in Europe which is issued and enforceable and the Board believes that any manufacture or use of products using isobaric tandem mass tags that come under the broad scope of the TMT‚® patent may need licences from Proteome Sciences.

It is not expected that this process will have any impact on the rapid growth and demand for isobaric mass tags technology nor should it have any effect on Proteome Sciences' ability to successfully conclude the outlicencing of TMT‚® reagents in the early part of 2008.

Ends

Contact Proteome Sciences plc at www.proteomics.com

Christopher Pearce, Chief Executive Officer

James Malthouse, Finance Director, Proteome Sciences plc

Dr. Ian Pike, Chief Business Officer, Proteome Sciences plc

Tel: +44 (0)1932 865065

Adrian Shaw, IKON Associates

Tel: +44 (0)1483 535102 / +44 (0)797 9900733

Matt Baldwin, COAST Communications

Tel: +44 (0)1233 503200

Shaun Dobson, Landsbanki Securities (UK) Ltd

Tel: +44 (0)207 426 9582

Gareth Price, Landsbanki Securities (UK) Ltd

Tel: +44 (0)207 426 9081

PROTEOME SCIENCES PLC
Date   Source Headline
26th Apr 20247:00 amRNSContract Win
10th Apr 20247:00 amRNSFinal Results
2nd Jan 20247:00 amRNSCompletion of new facility in San Diego
30th Nov 20237:00 amRNSTrading Update
2nd Oct 20237:00 amRNSLaunch of Single Cell Proteomics Services
30th Aug 20232:14 pmRNSInvestor Presentation
25th Aug 20237:00 amRNSInterim Results
1st Jun 20239:43 amRNSRepayment of Loan
17th May 20231:05 pmRNSResult of AGM
17th May 20237:00 amRNSAGM Statement
12th May 20237:00 amRNSExpansion into the US
14th Apr 202310:45 amRNSDirector/PDMR Shareholding
6th Apr 202311:34 amRNSDirector/PDMR Shareholding
6th Apr 202310:30 amRNSInvestor Presentation
4th Apr 20237:00 amRNSFinal Results
29th Mar 20237:00 amRNSNotice of Results
6th Mar 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:00 amRNSTrading Update
5th Jan 20237:00 amRNSMilestone Payment for TMT®/TMTpro™ Sales
1st Dec 20224:38 pmRNSGrant of Options and PDMR/director shareholdings
12th Oct 20227:00 amRNSGrant of Options and PDMR/director shareholdings
4th Oct 20227:00 amRNSChange of Auditor
20th Sep 20224:40 pmRNSSecond Price Monitoring Extn
20th Sep 20224:35 pmRNSPrice Monitoring Extension
18th Aug 20227:00 amRNSAppointment of Chief Financial Officer
11th Aug 20227:00 amRNSInvestor Presentation
4th Aug 20227:00 amRNSInterim Results
3rd Aug 20227:00 amRNSMilestone towards Single Cell Proteomics services
26th May 20229:04 amRNSChange of Registered Office
16th May 20221:24 pmRNSResult of AGM
16th May 20227:00 amRNSAGM Statement
12th May 20227:00 amRNSSubstantial Contract Win
26th Apr 20224:45 pmRNSDirector/PDMR Shareholding
21st Apr 20225:13 pmRNSDirector/PDMR Shareholding
11th Apr 20227:00 amRNSInvestor Presentation
1st Apr 20226:01 pmRNSDirector shareholding
31st Mar 20227:09 amRNSFinal Results
30th Mar 202211:24 amRNSLoan amendment
29th Mar 20227:00 amRNSNotice of Results
16th Feb 20224:40 pmRNSSecond Price Monitoring Extn
16th Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading Update
31st Dec 202112:36 pmRNSPrice Monitoring Extension
20th Dec 20217:00 amRNSSubstantial Contract Win
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20214:36 pmRNSPrice Monitoring Extension
26th Nov 20214:36 pmRNSPrice Monitoring Extension
5th Nov 20217:00 amRNSPRM,INmune Bio presenting biomarker discovery data
3rd Nov 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.